Physician profile
Gregory Daniel Spin
NPI 1114977386
$2,385.75
in general payments reported to CMS, 2019-2025
22 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $223 · 2021: $391 · 2022: $145 · 2023: $358 · 2024: $256 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Education: $43.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.71 |
| Education | $43.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $480.11 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $407.11 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $282.70 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $122.40 | 2019 | |
| Kyowa Kirin, INC. | $121.84 | 2024 | |
| Apellis Pharmaceuticals, INC. | $91.83 | 2025 | |
| Nxstage Medical, INC. | $91.73 | 2025 | Nxstage System One |
| Glaxosmithkline, LLC. | $75.87 | 2022-2023 | Jesduvroq, Benlysta |
| Baxter Healthcare | $68.25 | 2019 | |
| Amgen INC. | $64.96 | 2019-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $62.85 | 2023-2024 | Lupkynis |
| Akebia Therapeutics INC | $60.28 | 2019-2025 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $58.18 | 2019-2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.24 | 2023-2024 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $45.71 | 2025 | |
| Ardelyx, INC. | $34.92 | 2023 | Ibsrela |
| Calliditas Therapeutics US INC. | $34.92 | 2023-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $32.32 | 2024-2025 | |
| Daiichi Sankyo INC. | $24.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.39 | 2021 | |
| Novo Nordisk INC | $21.67 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Spin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.